Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block Mittal M; Raychaudhuri SPIndian J Dermatol Venereol Leprol 2010[Nov]; 76 (6): 602-8; quiz 609Anti-tumor necrosis factor (anti-TNF) agents have revolutionized treatment of psoriasis and many other inflammatory diseases of autoimmune origin. They have considerable advantages over the existing immunomodulators. Anti-TNF agents are designed to target a very specific component of the immune-mediated inflammatory cascades. Thus, they have lower risks of systemic side-effects. In a brief period of 10 years, a growing number of biological therapies are entering the clinical arena while many more biologicals remain on the horizon. With time, the long-term side-effects and efficacies of these individual agents will become clearer and help to determine which ones are the most suitable for long-term care. Golimumab (a human monoclonal anti-TNF-alpha antibody) and Certolizumab (a PEGylated Fab fragment of humanized monoclonal TNF-alpha antibody) are the two latest additions to the anti-TNF regimen. Here, we are providing a brief description about these two drugs and their uses.|Animals[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Certolizumab Pegol[MESH]|Humans[MESH]|Immunoglobulin Fab Fragments/immunology/*therapeutic use[MESH]|Polyethylene Glycols/*therapeutic use[MESH]|Psoriasis/*drug therapy/immunology[MESH]|Tumor Necrosis Factor Inhibitors[MESH]|Tumor Necrosis Factor-alpha/*antagonists & inhibitors/*immunology[MESH]|Tumor Necrosis Factors/immunology[MESH] |
